Jamjoom Pharma remains optimistic about Jamjoom Pharma’s product line and market-penetration strategy

BSF Capital comments on Jamjoom Pharma Q4 results, sets TP

JAMJOOM PHARMA(1.97%)

Jamjoom Pharma remains optimistic about Jamjoom Pharma’s product line and market-penetration strategy BSF Capital issued a report on Ja

To Access this Content, Please Login Or Register

To Access this Content, Please Login or Subscribe

Most Read